Diabetes, Mitral Repair And Diagnostics Drive Big Quarter For Abbott
The company’s worldwide medical devices business reported 10.6% organic growth for the third quarter of 2019.
Abbott Laboratories’ medical device businesses grew 10.6% year over year in the third quarter of 2019 while its diagnostics business grew 6.6%, helping the company grow 7.6% overall, the company reported on 16 October.
You may also be interested in...
Abbott’s Device And Diagnostics Businesses Maintain Growth Momentum In Q1
Abbott appears well-positioned to weather the pandemic with continued revenue growth in diabetes, heart failure devices and molecular diagnostics.
Abbott Launches REPAIR MR Trial To Bring MitraClip To More Patients
The 500-patient REPAIR MR trial will evaluate Abbott’s MitraClip mitral valve repair device in patients who would face moderate risk during open heart surgery. MitraClip is currently approved only for patients who are not surgical candidates.
MTI Outlook 2020: Medtechs Enter The Decade Of Digital, Consumers and Wellness
For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?